In DND-41 parental cells treated with Sotrastaurin, PKCδ inhibition alone significantly increased cMyc protein expression compared with DMSO-treated controls. Sotrastaurin substantially inhibited the regulatory–kinase domain interaction in SPASM PKCα sensors, as reported by changes in the FRET ratio. In PHGDH-overexpressing MHCC-97H cells supplemented with or without Sotrastaurin, the compound partially restored mitochondrial membrane potential. Following Sotrastaurin pretreatment and subsequent GSI treatment, continuous PKCδ inhibition completely abolished the rescue of cell growth in the comparison of untreated and Sotrastaurin-treated persister cells. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
cMyc Protein Expression in Parental Cells
Cell-based study · DND-41 parental cells [1]
DND-41 parental cells were treated with Sotrastaurin and compared with DMSO-treated controls. PKCδ inhibition alone resulted in a significant increase in cMyc protein expression.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- for 5 days
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Sotrastaurin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Notch and PKC inhibition synergistically affects resistant T-ALL cells’ survival (S215, S220, S235, S237); Results > PKCδ is indispensable for the development of adaptive GSI resistance (S272)
cMyc protein expression: cMyc protein expression; comparator: Ctrl DMSO-treated cells — Results > Notch and PKC inhibition synergistically affects resistant T-ALL cells’ survival (S237)
Regulatory–Kinase Domain Interaction in PKCα Sensors
Cell-based study · SPASM PKCα sensors [2]
SPASM PKCα sensors were treated with Sotrastaurin and compared with the no-inhibitor condition. Treatment substantially inhibited the regulatory–kinase domain interaction, as reported by changes in the FRET ratio.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- incubated at room temperature for 30 min before measurement
- Method
- Proteins were treated with inhibitors
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Sotrastaurin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Select ATP-competitive SMKIs displace regulatory-kinase domain interactions (S2, S5, S6); Experimental procedures > Experimental methods > FRET measurements (S99, S102); Figure 1 legend (S231)
regulatory-kinase domain interaction as reported by changes in the FRET ratio: regulatory-kinase domain interaction as reported by changes in the FRET ratio; comparator: no inhibitor condition (apo) — Results > Select ATP-competitive SMKIs displace regulatory-kinase domain interactions (S5, S6)
Mitochondrial Membrane Potential in PHGDH-Overexpressing Cells
Cell-based study · PHGDH-overexpressing MHCC-97H cells [3]
PHGDH-overexpressing MHCC-97H cells were supplemented with or without Sotrastaurin. Sotrastaurin partially restored mitochondrial membrane potential in this comparison.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM
- Exposure duration
- 24 h
- Method
- supplemented
- Co-treatment
- Other interventions in this design: PHGDH. Compound effect isolated by the comparison: PHGDH-overexpressing MHCC-97H cells supplemented with or without sotrastaurin.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Sotrastaurin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > PHGDH promotes mitophagy via PRKCD (S68, S69, S75)
mitochondrial membrane potential: mitochondrial membrane potential; comparator: PHGDH-overexpressing MHCC-97H cells supplemented with or without sotrastaurin — Results > PHGDH promotes mitophagy via PRKCD (S69, S75)
Cell Growth Rescue in Drug-Tolerant Persister Cells
Cell-based study · DND-41 parental cells [1]
DND-41 parental cells were pretreated with Sotrastaurin before GSI treatment. In the comparison of untreated and Sotrastaurin-treated persister cells under GSI treatment, continuous PKCδ inhibition completely abolished the rescue of cell growth.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- pretreated with sotrastaurin (5 μM) for 3 days. Next, GSI treatment (0.5 μM) was performed up to 5 weeks
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: GSI 0.5 μM. Compound effect isolated by the comparison: untreated and sotrastaurin-treated persister cells.
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Sotrastaurin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > PKCδ is indispensable for the development of adaptive GSI resistance (S264, S265, S266, S272, S273, S274); Methods > Drug treatment (S294)
Live cell count was performed by trypan blue exclusion: Live cell count was performed by trypan blue exclusion; comparator: persister cells (DMSO + GSI) — Results > PKCδ is indispensable for the development of adaptive GSI resistance (S266, S274)